The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity

A. M. Hopkins, C. E. O'Doherty, D. J.R. Foster, V. Suppiah, R. N. Upton, L. D. Spargo, L. G. Cleland, S. M. Proudman, M. D. Wiese

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

What is known and objective A common polymorphism (C1858T) in the gene that encodes the protein tyrosine phosphatase non-receptor type 22 (PTPN22) is associated with altered T-cell responses and increased susceptibility to rheumatoid arthritis (RA) and other autoimmune diseases. Teriflunomide, the active metabolite of leflunomide, reduces T-cell responses through inhibition of tyrosine kinase p56LCK. We examined a potential association between PTPN22 genotype and response or toxicity to leflunomide in Caucasian RA patients taking leflunomide in combination with other disease-modifying antirheumatic drugs (DMARDs). Methods Patients enrolled in the Royal Adelaide Hospital RA inception cohort and taking leflunomide were eligible for inclusion. Participants were followed for 12 months after leflunomide initiation or until either another DMARD was added or leflunomide was ceased. Clinical response according to change in 28-joint Disease Activity Score (DAS28) and cessation due to toxicity were assessed. Results and discussion A total of 94 participants were included in the study, 75 of whom carried the CC genotype, 18 the CT, whereas one individual carried the TT genotype. Over the first 12 months of leflunomide treatment, there was no statistically significant relationship between carrying the T allele and change in DAS28 (-0·84 vs. -1·15, P = 0·446) nor with cessation of leflunomide treatment due to side effects (P = 0·433). These results indicate that PTPN22 C1858T genotype has no effect on response or toxicity outcomes in leflunomide-treated RA patients. What is new and conclusion This is the first study to evaluate the biologically plausible hypothesis that PTPN22 genotype might be a predictor of response/toxicity to leflunomide therapy. Despite this, PTPN22 genotype was not associated with leflunomide response or toxicity in patients with RA.

Original languageEnglish
Pages (from-to)555-560
Number of pages6
JournalJournal of Clinical Pharmacy and Therapeutics
Volume39
Issue number5
DOIs
Publication statusPublished or Issued - Oct 2014
Externally publishedYes

Keywords

  • PTPN22
  • leflunomide
  • pharmacogenomics
  • polymorphism
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this